Perioperative prophylaxis with ertapenem reduced infections caused by extended-spectrum betalactamase-producting Enterobacteriaceae after kidney transplantation.


Journal

BMC nephrology
ISSN: 1471-2369
Titre abrégé: BMC Nephrol
Pays: England
ID NLM: 100967793

Informations de publication

Date de publication:
22 07 2019
Historique:
received: 15 03 2019
accepted: 09 07 2019
entrez: 24 7 2019
pubmed: 25 7 2019
medline: 24 11 2020
Statut: epublish

Résumé

In recent years we have witnessed an increase in infections due to multidrug-resistant organisms in kidney transplant recipients (KTR). In our setting, we have observed a dramatic increase in infections caused by extended-spectrum betalactamase-producing (ESBL) Enterobacteriaceae in KTR. In 2014 we changed surgical prophylaxis from Cefazolin 2 g to Ertapenem 1 g. We compared bacterial infections and their resistance phenotype during the first post-transplant month with an historical cohort collected during 2013 that had received Cefazolin. During the study period 110 patients received prophylaxis with Cefazolin and 113 with Ertapenem. In the Ertapenem cohort we observed a non-statistically significant decrease in the percentage of early bacterial infection from 57 to 47%, with urine being the most frequent source in both. The frequency of infections caused by Enterobacteriaceae spp. decreased from 64% in the Cefazolin cohort to 36% in the Ertapenem cohort (p = 0.005). In addition, percentage of ESBL-producing strains decreased from 21 to 8% of all Enterobacteriaceae isolated (p = 0.015). After adjusted in multivariate Cox regression analysis, male sex (HR 0.16, 95%CI: 0.03-0.75), cefazolin prophylaxis (HR 4.7, 95% CI: 1.1-22.6) and acute rejection (HR 14.5, 95% CI: 1.3-162) were associated to ESBL- producing Enterobacteriaceae infection. Perioperative antimicrobial prophylaxis with a single dose of Ertapenem in kidney transplant recipients reduced the incidence of early infections due to ESBL-producing Enterobacteriaceae without increasing the incidence of other multidrug-resistant microorganisms or C. difficile.

Identifiants

pubmed: 31331289
doi: 10.1186/s12882-019-1461-4
pii: 10.1186/s12882-019-1461-4
pmc: PMC6647261
doi:

Substances chimiques

Anti-Bacterial Agents 0
Ertapenem G32F6EID2H
Cefazolin IHS69L0Y4T

Types de publication

Comparative Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

274

Références

J Antimicrob Chemother. 2003 Sep;52(3):331-44
pubmed: 12917243
Liver Transpl. 2004 Jul;10(7):817-27
pubmed: 15237363
Clin Microbiol Rev. 2005 Oct;18(4):657-86
pubmed: 16223952
Crit Care Med. 2007 Jan;35(1):89-95
pubmed: 17110877
N Engl J Med. 2006 Dec 21;355(25):2640-51
pubmed: 17182989
J Biol Chem. 2007 Oct 19;282(42):30414-22
pubmed: 17646161
Transplant Proc. 2007 Sep;39(7):2222-4
pubmed: 17889144
Nat Clin Pract Nephrol. 2008 May;4(5):252-64
pubmed: 18334970
Am J Transplant. 2008 May;8(5):1000-5
pubmed: 18727176
Transplant Proc. 2009 Jul-Aug;41(6):2262-4
pubmed: 19715892
Clin Infect Dis. 2010 Mar 1;50(5):625-63
pubmed: 20175247
J Clin Microbiol. 2010 May;48(5):1726-31
pubmed: 20181897
Clin Infect Dis. 2011 Mar 1;52(5):e103-20
pubmed: 21292654
Crit Care. 2011;15(1):R55
pubmed: 21306623
Clin Microbiol Infect. 2012 Mar;18(3):268-81
pubmed: 21793988
Clin Transplant. 2012 May-Jun;26(3):437-42
pubmed: 22004051
Antimicrob Agents Chemother. 2012 Jun;56(6):3409-12
pubmed: 22450984
Emerg Infect Dis. 2012 Jun;18(6):908-16
pubmed: 22607885
Transplant Proc. 2012 Dec;44(10):3029-32
pubmed: 23195020
Braz J Infect Dis. 2013 Mar-Apr;17(2):254-5
pubmed: 23453411
Surg Infect (Larchmt). 2013 Feb;14(1):73-156
pubmed: 23461695
Antimicrob Agents Chemother. 2013 Sep;57(9):4512-7
pubmed: 23836184
Transplantation. 2013 Nov 15;96(9):843-9
pubmed: 23883973
Ann Surg Oncol. 2014 Feb;21(2):513-9
pubmed: 24114052
Clin Microbiol Infect. 2014 Jan;20 Suppl 1:1-55
pubmed: 24329732
Transpl Infect Dis. 2014 Apr;16(2):171-87
pubmed: 24661423
Clin Microbiol Infect. 2014 Sep;20 Suppl 7:49-73
pubmed: 24861521
J Antimicrob Chemother. 2014 Dec;69(12):3379-86
pubmed: 25151205
Surgery. 2015 Jan;157(1):104-10
pubmed: 25304836
J Antimicrob Chemother. 2015 Mar;70(3):914-21
pubmed: 25480492
Am J Transplant. 2015 Apr;15(4):1021-7
pubmed: 25676738
Crit Care. 2015 May 04;19:218
pubmed: 25936721
Clin Microbiol Infect. 2015 Dec;21(12):1104.e1-8
pubmed: 26235196
PLoS One. 2015 Aug 03;10(8):e0134737
pubmed: 26237422
Virulence. 2016 Apr 2;7(3):329-40
pubmed: 26766415
BMC Nephrol. 2017 May 19;18(1):164
pubmed: 28525997
Clin Transplant. 2019 Feb 21;:e13507
pubmed: 30793386
Am J Infect Control. 1996 Oct;24(5):380-8
pubmed: 8902113
Nephrol Dial Transplant. 1998 Jul;13(7):1637-41
pubmed: 9681704

Auteurs

Gemma Sanclemente (G)

Department of Infectious Diseases, Hospital Clinic - IDIBAPS, University of Barcelona, Villarroel 170, 08036, Barcelona, Spain.

Marta Bodro (M)

Department of Infectious Diseases, Hospital Clinic - IDIBAPS, University of Barcelona, Villarroel 170, 08036, Barcelona, Spain. mbodro@clinic.ub.es.

Carlos Cervera (C)

Department of Infectious Diseases, Hospital Clinic - IDIBAPS, University of Barcelona, Villarroel 170, 08036, Barcelona, Spain.

Laura Linares (L)

Department of Infectious Diseases, Hospital Clinic - IDIBAPS, University of Barcelona, Villarroel 170, 08036, Barcelona, Spain.

Frederic Cofán (F)

Kidney Transplant Unit, Hospital Clinic - IDIBAPS, University of Barcelona, Barcelona, Spain.

Francesc Marco (F)

Department of Microbiology, Centre Diagnòstic Biomèdic (CDB), Instituto de Salud Global de Barcelona (ISGlobal), Hospital Clinic - IDIBAPS, University of Barcelona, Barcelona, Spain.

Jordi Bosch (J)

Department of Microbiology, Centre Diagnòstic Biomèdic (CDB), Instituto de Salud Global de Barcelona (ISGlobal), Hospital Clinic - IDIBAPS, University of Barcelona, Barcelona, Spain.

Federico Oppenheimer (F)

Kidney Transplant Unit, Hospital Clinic - IDIBAPS, University of Barcelona, Barcelona, Spain.

Fritz Dieckmann (F)

Kidney Transplant Unit, Hospital Clinic - IDIBAPS, University of Barcelona, Barcelona, Spain.

Asunción Moreno (A)

Department of Infectious Diseases, Hospital Clinic - IDIBAPS, University of Barcelona, Villarroel 170, 08036, Barcelona, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH